Risk factors for resistance to β-lactam/β-lactamase inhibitors and ertapenem in Bacteroides bacteremia

Janessa M. Smith, Edina Avdic, Pranita Tamma, Long Zhang, Karen C Carroll, Sara Cosgrove

Research output: Contribution to journalArticle

Abstract

The objective of this study was to determine risk factors for the development of resistance to β-lactams/β-lactamase inhibitors (βL/βLIs) and ertapenem among Bacteroides species bacteremia. We conducted a retrospective case-control study of 101 adult patients with Bacteroides species bacteremia at a 1,051-bed tertiary care medical center. The duration of exposure to βL/βLIs (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.08 to 2.31) was the only independent risk factor for resistance.

Original languageEnglish (US)
Pages (from-to)5049-5051
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Lactams
Bacteroides
Bacteremia
Tertiary Care Centers
Case-Control Studies
Odds Ratio
Confidence Intervals
ertapenem

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Risk factors for resistance to β-lactam/β-lactamase inhibitors and ertapenem in Bacteroides bacteremia. / Smith, Janessa M.; Avdic, Edina; Tamma, Pranita; Zhang, Long; Carroll, Karen C; Cosgrove, Sara.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 8, 01.08.2015, p. 5049-5051.

Research output: Contribution to journalArticle

@article{1bb620a21a814d4c9828dee570710810,
title = "Risk factors for resistance to β-lactam/β-lactamase inhibitors and ertapenem in Bacteroides bacteremia",
abstract = "The objective of this study was to determine risk factors for the development of resistance to β-lactams/β-lactamase inhibitors (βL/βLIs) and ertapenem among Bacteroides species bacteremia. We conducted a retrospective case-control study of 101 adult patients with Bacteroides species bacteremia at a 1,051-bed tertiary care medical center. The duration of exposure to βL/βLIs (odds ratio [OR], 1.25; 95{\%} confidence interval [CI], 1.08 to 2.31) was the only independent risk factor for resistance.",
author = "Smith, {Janessa M.} and Edina Avdic and Pranita Tamma and Long Zhang and Carroll, {Karen C} and Sara Cosgrove",
year = "2015",
month = "8",
day = "1",
doi = "10.1128/AAC.00046-15",
language = "English (US)",
volume = "59",
pages = "5049--5051",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Risk factors for resistance to β-lactam/β-lactamase inhibitors and ertapenem in Bacteroides bacteremia

AU - Smith, Janessa M.

AU - Avdic, Edina

AU - Tamma, Pranita

AU - Zhang, Long

AU - Carroll, Karen C

AU - Cosgrove, Sara

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The objective of this study was to determine risk factors for the development of resistance to β-lactams/β-lactamase inhibitors (βL/βLIs) and ertapenem among Bacteroides species bacteremia. We conducted a retrospective case-control study of 101 adult patients with Bacteroides species bacteremia at a 1,051-bed tertiary care medical center. The duration of exposure to βL/βLIs (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.08 to 2.31) was the only independent risk factor for resistance.

AB - The objective of this study was to determine risk factors for the development of resistance to β-lactams/β-lactamase inhibitors (βL/βLIs) and ertapenem among Bacteroides species bacteremia. We conducted a retrospective case-control study of 101 adult patients with Bacteroides species bacteremia at a 1,051-bed tertiary care medical center. The duration of exposure to βL/βLIs (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.08 to 2.31) was the only independent risk factor for resistance.

UR - http://www.scopus.com/inward/record.url?scp=84939865005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939865005&partnerID=8YFLogxK

U2 - 10.1128/AAC.00046-15

DO - 10.1128/AAC.00046-15

M3 - Article

VL - 59

SP - 5049

EP - 5051

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -